AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 101 min read$VTGN

Vistagen Therapeutics, Inc. (VTGN): Submission of Matters to a Vote of Security Holders

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 10, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholde

Original reporting
SEC EDGAR 8-K
Published Sep 10, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$VTGN
Neutral
high confidence
Mentioned
$VTGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VTGNNeutralLow
01

Why it matters

The meeting results confirm the election of four directors, approval of executive compensation on an advisory basis, and ratification of KPMG as auditor. These are routine items with negligible market impact.

02

Market read

The filing is a routine governance update with minimal relevance to traders.

03

What to watch

Potential future proxy battles if director composition changes, but not evident now.

Relevance 6/10Novelty 3/10Timing: September 10, 2026 (filing date)

Background

Vistagen Therapeutics filed an 8‑K to disclose its 2026 Annual Meeting outcomes, a standard corporate governance filing.

Company-level read

Ticker impact

$VTGNNeutralHigh confidence
Context

SEC 8‑K reports Vistagen's annual meeting results, including director elections, say‑on‑pay approval and auditor ratification.

Expected impact

minimal; likely no significant move.

Evidence & confidence

Annual meeting outcomes are expected and material only for governance compliance, not for valuation.

Market effects

Sector

None; governance update does not affect sector trends.

Regional

None; company is US‑based with limited broader market relevance.

Global

None

Counterpoint

What could challenge this read

No contrarian angle; the filing is routine.

Key entities

  • company
    Vistagen Therapeutics, Inc.

    Biopharma company filing the 8‑K.

  • service_provider
    KPMG LLP

    Appointed auditor for fiscal year ending March 31, 2027.

Read at source← All news

Related articles

SEP 24
$VTGNMedAI 8/10

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s websi

SEC EDGAR 8-K2 min
SEP 22
$VTGNMedAI 8/10

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social…

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new

SEC EDGAR 8-K2 min
AUG 14
$VTGNMed

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA eng

SEC EDGAR 8-K6 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min